On Thursday, Shares of Viacom, Inc. (NASDAQ:VIAB), gained 2.33% to $49.65.
Viacom Inc., released its 2015 Social Impact Review: Raising Voices. The annual social responsibility report showcases the many ways the company leverages its platforms to raise audiences’ voices toward driving change.
For the first time, the Social Impact Review outlines specific and distinct social responsibility aims, setting benchmarks for growth and campaign participation in each of our areas of impact, counting: Building Inclusive Societies, Pioneering Social Change, Promoting Healthy Living, and Inspiring Future Generations.
Viacom Inc. operates as an entertainment content company in the United States and internationally. The company creates television programs, motion pictures, short-form video, applications, games, consumer products, social media, and other entertainment content.
Shares of RXi Pharmaceuticals Corp (NASDAQ:RXII), declined -9.41% to $0.432, during its last trading session.
RXi Pharmaceuticals Corporation, declared that it has selected two compounds for cosmetic product development (“cosmeceuticals”) based on its proprietary self-delivering RNAi (sd-rxRNA®) platform.
RXI-231, an sd-rxRNA compound developed to target Tyrosinase (TYR), has been selected to advance in to cosmetic product development. TYR is a key enzyme in the synthesis of melanin, the pigment that gives human skin, hair and eyes their color. RXI-231 lead to a visible reduction of pigmentation in melanocytes in a 3-dimensional tissue culture model of human epidermis. Results in this model show that RXI-231 is about one hundred times more potent than kojic acid, a well-characterized skin lightening agent.
RXI-185, an sd-rxRNA compound developed to target Collagenase (MMP1), has been selected to advance in to cosmetic product development. Collagenases are enzymes that break the peptide bonds in collagen. Matrix metalloproteinase 1 (MMP1) is a collagenase involved in the breakdown of extracellular matrix that specifically cleaves collagen I, II and III. Results from studies show a pronounced reduction in MMP1 mRNA levels that correspond to a similar reduction in MMP1 enzyme activity in cell culture in vitro. RXI-185 is nominated for development as a product that may improve skin appearance.
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents. Its clinical development programs comprise RXI-109, a self-delivering RNAi compound, which is in Phase IIa clinical trial that is used to prevent or reduce dermal scarring following surgery or trauma, in addition to for the administration of hypertrophic scars and keloids; and Samcyprone, an immunomodulation agent, which is in Phase IIa clinical trial for the treatment of various disorders, such as alopecia areata, warts, and cutaneous metastases of melanoma.
Finally, Shares of EP Energy Corp (NYSE:EPE), ended its last trade with 0.17% gain, and closed at $5.86.
EP Energy Corporation, has planned a webcast at 10:00 a.m. Eastern Time, 9:00 a.m. Central Time, on Thursday, October 29, 2015 to discuss its third quarter 2015 financial and operational results. The company’s third quarter earnings press release is planned to be issued after the New York Stock Exchange closes trading on Wednesday, October 28, 2015.
The webcast may be accessed online through the company’s website at epenergy.com in the Investor Center. Materials to be talked about during the webcast will be available in the Investor Center one hour preceding to the webcast.
EP Energy Corporation, an independent exploration and production company, acquires and develops unconventional onshore oil and natural gas properties in the United States. The company primarily holds interests in various properties covering about 440,000 net acres that are located in various areas comprising Eagle Ford Shale, South Texas; Wolfcamp Shale, the Permian Basin, West Texas; the Altamont field in the Uinta Basin, northeastern Utah; and Haynesville Shale, North Louisiana.